

DIGNITANA

Press release on 10 February 2020

Dignitana's extraordinary general meeting

Today, on 10 February 2020, Dignitana AB (publ) held an extraordinary general meeting ("EGM") in Lund, Sweden. The EGM elected advokat Eddie Juhlin with Fredersen Advokatbyrå as chairman of the meeting and jur. kand. Anton Walfridsson with Fredersen Advokatbyrå to take minutes at the meeting. The EGM resolved upon, inter alia, the following resolutions.

Resolution concerning issue and transfer of warrants to key persons in the Dignitana group

The EGM resolved on the issue and transfer of warrants to key persons in accordance with the proposal made by the board of directors.

The resolution entail that the company issues at most 2,500,000 warrants, each entitling the holder to subscribe for one new share in the company. The warrants are issued to a wholly owned subsidiary to Dignitana for transfer to current and future key persons in the group, in accordance with the proposal which was included in the notice to the EGM and which is available on the company's website, www.dignitana.com.

Upon full utilization of the warrants resolved upon by the EGM as well as the outstanding warrants of series 2017/2020, the dilution effect amounts to approximately 4.5 percent of the total amount of outstanding shares and votes in the company. The dilution effect has been calculated as the number of additional shares and votes if the warrants are fully utilized in relation to the sum of the current number of shares and votes and the number of additional shares and votes at full utilization of the warrants.

For further information, please contact:

William Cronin, CEO, Dignitana AB
+1 469-518-5031
investorrelations@dignitana.com

Certified advisor

Erik Penser Bank AB
Box 7405,
103 91 Stockholm
Phone: +46 8-463 83 00
E-mail: certifiedadviser@penser.se

About Dignitana

Dignitana AB is the world leader in clinically superior scalp cooling technology. The company produces The DigniCap® Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy. FDA cleared since 2015, DigniCap provides continuous cooling with high efficacy, safety and patient comfort. Hailed internationally as a life-changing medical advancement for cancer patients, The DigniCap Scalp Cooling System was invented in 1999 by a Swedish Oncology nurse and has been available in Europe since 2001. Dignitana AB is listed on Nasdaq First North Growth Market in Sweden with headquarters in Lund, Sweden and operations based in Dallas, Texas in the United States. Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Learn more at www.dignitana.se and www.dignicap.com.